PAR-24-027
Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
Summary
PAR-24-027: PATH Study Biospecimen Access (X01)
Research Focus
This funding opportunity provides access to biospecimens and longitudinal data from the Population Assessment of Tobacco and Health (PATH) Study, a national cohort study designed to generate epidemiologic evidence on tobacco use behaviors, exposures, and health outcomes. The PATH Study is a collaboration between the National Institute on Drug Abuse (NIDA), NIH, and the FDA's Center for Tobacco Products (CTP), launched in 2011 to inform FDA regulatory activities under the Family Smoking Prevention and Tobacco Control Act.
Researchers can access stored biospecimens (urine, serum, plasma, and genomic DNA) collected from approximately 46,000 participants—including youth (12–17 years), adults (18+ years), and diverse tobacco product users, former users, and non-users—across four annual waves (2013–2017) and three biennial waves (2018–2023). Questionnaire data include tobacco use behaviors, addiction and cessation patterns, exposures, attitudes, beliefs, and health status. Studies addressing tobacco regulatory science priorities or expanding knowledge of tobacco use and related health outcomes are prioritized; exploratory and pilot studies are eligible.
At a Glance
- Who can apply: Higher education institutions, nonprofits, for-profit organizations, government agencies, tribal governments, faith-based organizations, and other U.S. entities. Foreign institutions are not eligible.
- Funding & project length: No funds awarded; mechanism provides access to biospecimens and data. Maximum project period 5 years.
- Award mechanism: X01 Resource Access Award (not a grant or cooperative agreement).
- Key dates: Applications due April 30, July 31, October 31, 2024 and rolling quarterly thereafter through October 30, 2026. Applicants must contact PATH Study team at least 5 months before submission to confirm biospecimen availability.
- Best fit for: Tobacco regulatory science, epidemiology, biomarker research, and public health studies using longitudinal cohort data and biospecimen analysis in diverse U.S. populations.
Key Facts
Deadline
Fri, October 30, 2026
Posted
Thu, August 24, 2023
Max Duration
5 years
Keywords
Research Areas
Gotchas (3)
Applicants must contact the PATH Study team at least five months in advance of application submission deadlines to confirm biospecimen availability and obtain written confirmation before submitting an
95%
Source Text
“Interested applicants are required to contact the PATH Study team at least five months in advance of the application submission deadlines to determine whether there is sufficient quantity of the biospecimens required for the proposed study. Applications must include written confirmation from the PATH Study team indicating sufficient numbers of biospecimens.”
The maximum project period is 5 years, which is a constraint on award duration that applicants must respect in project planning.
85%
Source Text
“Award Project Period: The scope of the proposed project should determine the project period. The maximum project period is 5 years.”
Studies addressing PATH Study objectives and tobacco regulatory science research priorities receive highest priority; other studies expanding knowledge of tobacco use receive lower priority. This crea
90%
Source Text
“Investigators proposing meritorious and feasible studies including exploratory or pilot studies, consistent with PATH Study objectives and/or research priorities for tobacco regulatory science will be given the highest priority for access to PATH Study biospecimens. Studies that address other objectives that expand the knowledge of tobacco use and/or tobacco related health outcomes will also be considered but will be a lower priority.”